Collin joined Foresite Capital in 2016 as a member of the investment team and focuses on evaluating investment opportunities of private and public biotech companies. Collin serves as a board observer for Avenzo Therapeutics and RayThera. Collin previously served as a board observer at XinThera (acquired by Gilead Sciences).
Collin started his career as an investment banking analyst in the Healthcare Group at Bank of America Merrill Lynch, where he focused on biopharma mergers & acquisitions and capital markets transactions.
Collin received a B.S. in Bioengineering with a concentration in Biotechnology from the University of California, San Diego.